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Abstract
Myelomeningocele (MMC), the most severe form of spina biﬁda
(SB), causes neurological deﬁcit. Injury to the spinal cord is thought
to begin in utero. We investigated whether brain–speciﬁc proteins
(BSP) would enable us to monitor the development of MMC-related
tissue damage during pregnancy in an animal model with naturally–
occurring SB (curly tail/loop tail mouse, n=256). Amniotic ﬂuid lev-
els of the neuroﬁlament heavy chain (NfH), GFAP and S100B were
measured by standard ELISA techniques. The amniotic ﬂuid levels
of all BSP were similar in SB and control mice on embryonic days
(E) 12.5 and 14.5, whereas a signiﬁcant increase was observed for
GFAP in SB mice on E16.5. All BSP were signiﬁcantly elevated in
SB mice on E18.5. The rapid increase of GFAP which is parallelled
by a moderate increase in NfH and S100B suggests that spinal cord
damage starts to accelerate around E16.5. The macroscopic size of
the MMC was related to NfH level on E16.5 and E18.5, suggesting
that axonal degeneration is most severe in large MMC. Amniotic ﬂuid
BSP measurements may provide important information for balanc-
ing the risks and beneﬁts to mother and child of in utero surgery for
myelomeningocele.
Keywords neuroﬁlaments, NfH, glial ﬁbrillary acidic protein, GFAP, S100B,
surrogate marker, biomarker, fetal surgery, neural tube defects, spina bi-
ﬁdaBSP in spina biﬁda 3
Introduction
Myelomeningocele (MMC) is a clinically important neural tube defect that
arises during embryonic development as a result of abnormal primary neu-
rulation.1 Common physical problems associated with MMC include vary-
ing degrees of sensorimotor neurological deﬁcit, urogenital and intestinal
dysfunction, skeletal malformations and hydrocephalus. The widely ac-
cepted concept of a predominantly intrinsic aetiology for the sensorimotor
deﬁcit in MMC has recently been challenged by data derived from ani-
mal models with surgically created MMC.2–4 It was suggested that direct
trauma to the exposed fetal spinal cord might occur in utero, thereby elic-
iting secondary damage to the spinal nerves, so that timely in utero cov-
erage of the MMC may improve the postnatal outcome.2,5,6 Although it
was suggested previously that a Cesarean section may minimise mechan-
ical stress during labour, and improve postnatal outcome,7 severe damage
to the exposed spinal cord may have already occurred long before birth.
Support for this idea comes from detailed immunohistochemical investiga-
tion of surgically created MMC, which demonstrated massive spinal cord
astrocytosis at fetal stages,2 and electrophysiological examination which
suggested substantial axonal loss at similar stages.8,9 Both astrocytosis
and axonal loss are pathological features which can be monitored by mea-
suring brain-speciﬁc proteins.10
In the present experimental study we were interested in monitoring
the onset and development of the spinal cord injury in MMC at a cellularBSP in spina biﬁda 4
level. The model chosen was the curly tail/loop tail mouse model, which
has a high frequency of naturally–occurring spina biﬁda (SB).11 Astrocyto-
sis was estimated by quantifying glial ﬁbrillary acidic protein (GFAP) and
S100B.12,13 Neuro–axonal injury was estimated by measuring the neuro-
ﬁlament heavy chain (NfH).14 The study aimed to determine the extent of
spinal cord injury in relation to gestational age and size of the SB lesion.
Material and Methods
Mouse strains and sample collection This study and experimental pro-
cedures have been approved by the local ethics committee according to
the Declarations of Helsinki and as required under the Animals (Scien-
tiﬁc Procedures) Act 1986 of the UK Government. The rules of laboratory
animal care (NIH publication No. 86-23) were followed.
Mutant curly tail and loop tail mice were maintained as separate colonies
on a 12 h light–dark cycle (lights on from 07.00 to 19.00). Doubly heterozy-
gous males (Lp/+; ct/+) were mated overnight with homozygous curly tail
females (+/+; ct/ct) which were checked for copulation plugs the following
morning. The day of ﬁnding a plug was designated as embryonic day (E)
0.5. Matings generated litters with three different phenotypes: 40.5% of
mice had straight tails, 25.5% had curly tails, and 34% had spina biﬁda
(SB), usually with a curly tail. SB animals always showed lesions in the
lumbosacral region that extended to the tip of the tail. Experimental litters
were collected by sacriﬁcing pregnant females by cervical dislocation atBSP in spina biﬁda 5
E12.5, E14.5, E16.5 and E18.5. The extraembryonic membranes were in-
cised and amniotic ﬂuid was poured directly into a 1.5 mL Eppendorf tube.
Approximately 50 to 100 L of amniotic ﬂuid could be collected per fe-
tus. Samples were immediately snap–frozen in liquid nitrogen. The coded
samples were then stored at -70◦C until further analysis.
Control animals (n=134) were those that had neither an MMC lesion
nor sensorimotor deﬁcit of the hind–limbs. Animals with either a straight or
curly tail were included in the control group. MMC lesions were classiﬁed
as either large or small based on the ratio of total body size to MMC size
(see Figure 1 and Table 1). A ratio smaller than 10 indicated a large MMC
whereas a ratio larger than 10 represented a small MMC. Of 122 animals
with a macroscopically visible SB, the MMC was large in 36 cases and
small in 84 cases. Two MMC animals were inadvertently discarded before
classiﬁcation of lesion size.
Brain–speciﬁc proteins The phosphorylated neuroﬁlament heavy chain
(NfHSMI35 ), glial ﬁbrillary acidic protein (GFAPSMI26 ) and S100B were quan-
tiﬁed as described.12–14 The structure of these proteins is largely con-
served across species and the assays have previously been used on tis-
sue from another mouse model.10 Due to the small sample volume a max-
imum of two BSP could be measured per animal.
Statistical analysis All statistical analyses were performed and graphs
prepared using SAS software (version 8.2, SAS Institute, Inc., Cary, NorthBSP in spina biﬁda 6
Carolina, USA). Because of non–Gaussian distribution of the BSP data,
the median values and the 25–75 % interquartile range (IQR) are shown.
Independent variables were compared using the non-parametric Wilcoxon
test. If signiﬁcance was based on small numbers the results were checked
by the Fisher’s exact test. The cut–off for categorical data analysis was
set to the 100% cumulative frequency of the indicated control group. The
linear correlation between continuous variables was evaluated using the
Spearman correlation coefﬁcient (=0.05). Linear regression analysis was
performed using the least–squares method. P–values <0.05 were consid-
ered as signiﬁcant.
Results
In control mice there was no correlation between gestational age and ei-
ther GFAP or NfH levels. In contrast S100B concentration increased with
age in control mice (R=0.58, p<0.01). This correlation was caused by a
signiﬁcant increase in S100B between E16.5 and E18.5 (p<0.01).
GFAP The concentration of amniotic ﬂuid GFAP differed signiﬁcantly be-
tween control and SB groups (F7;153=37.89, p<0.001, Figure 2). Post–hoc
analysis revealed that this was due to a 100–fold increase of GFAP level
in SB mice at E16.5 (p<0.001, Table 2). At E18.5 GFAP levels in the am-
niotic ﬂuid of SB mice were still approximately 50–fold higher compared to
controls (p<0.001).BSP in spina biﬁda 7
The analysis of GFAP concentration in relation to SB lesion size did not
reveal any signiﬁcant difference between large and small MMC lesions.
S100B The concentration of amniotic ﬂuid S100B differed signiﬁcantly
between control and SB groups (F7;99=7.62, p<0.001). Post-hoc analysis
revealed a signiﬁcant difference between SB and control mice at E18.5
(p<0.05, Table 1), but not at earlier stages. There was a correlation
(R=0.69, p<0.01) between S100B and GFAP in SB (n=16) but not in con-
trol (n=16) mice.
The analysis of S100B concentration in relation to SB lesion size did
not reveal any signiﬁcant difference between large and small MMC lesions.
NfH The concentration of amniotic ﬂuid NfH differed signiﬁcantly between
control and SB groups (F7;91=3.66, p<0.01). Post–hoc analysis revealed a
signiﬁcant difference between SB and control mice at E16.5 (p<0.01) and
at E18.5 (p<0.01, Table 2).
Moreover, the analysis of NfH concentration in relation to SB lesion size
revealed a signiﬁcant difference (F5;37=7.98, p<0.001). A large MMC was
associated with higher amniotic ﬂuid NfH levels than a small MMC lesion
at both E16.5 (p<0.001) and E18.5 (p<0.01, Figure 3).BSP in spina biﬁda 8
Discussion
The ﬁndings of this study demonstrate a 100–fold increase in amniotic ﬂuid
GFAP at E16.5 in SB mice when compared to controls. We interpret this
sudden, dramatic increase in GFAP concentration as indirect evidence that
spinal cord injury may accelerate at this time.
GFAP levels started to rise in SB mice at E16.5 compared to the rela-
tively uniform levels observed in SB and control mice at E12.5 and E14.5,
and in controls at later stages. GFAP levels remained signiﬁcantly higher in
SB compared to control mice at E18.5, but the difference was less marked
(50–fold). This could possibly be due to a protein “wash–out pattern” as
observed for S100B in human cerebrospinal ﬂuid.15 Alternatively it may be
caused by post–translational modiﬁcations such as citrullination16 or ag-
gregate formation, both of which could potentially interfere with the binding
characteristics of the capture antibody in the ELISA. Finally, one needs to
consider a “burnt–out” pattern, in which the overall loss of astrocytes on
E16.5 is so great that further damage to remaining cells at the site of the
MMC results in a less marked elevation of GFAP.
In support of our hypothesis, there is evidence that GFAP concentra-
tion is also elevated in human amniotic ﬂuid taken from second-trimester
pregnancies with spina biﬁda and other neural tube defects.17–19 Interest-
ingly, Van Regemorter et al.19 describe a mean GAFP concentration of 1
ng/mL in spina biﬁda pregnancies samples prior to 24 weeks, but a con-
centration of 3 ng/mL in amniotic ﬂuids of spina biﬁda pregnancies beyondBSP in spina biﬁda 9
24 weeks (Table 2 in19). This ﬁnding parallels our observation of an in-
creased GFAP concentration in late-stage mouse fetuses with SB. On the
other hand analysis of a large number of human second trimester pregnan-
cies revealed that staining for cells containing GFAP did not improve the
diagnostic sensitivity or speciﬁcity of amniotic ﬂuid alpha–fetoprotein and
acetylcholinesterase.20 It may be that the measurement of GFAP protein
itself, rather than staining for GFAP positive cells may be a more sensi-
tive technique, particularly if the release of GFAP into the amniotic ﬂuid is
secondary to the death of astrocytes at the site of the MMC lesion.
Amniotic ﬂuid S100B levels have not been investigated systematically
with regard to spina biﬁda, but one group found S100B to be of use in
general prenatal screening.21,22 In the present study there was a moder-
ate, but signiﬁcant, increase in amniotic ﬂuid S100B at E18.5, although
this was not conﬁned to SB animals. The ﬁnding of an increase in S100B
concentration at late gestation even in control amniotic ﬂuids suggests a
possible physiological role for this protein. Indeed, S100B has cytokine
properties which can be neurotrophic at certain concentrations (reviewed
in23). Additionally, the measurement of S100B from body ﬂuids might re-
ﬂect sources other than the nervous system, such as placenta, adipose
tissue, testis and skin.21,24–26 The ﬁnding of a correlation between S100B
and the relatively speciﬁc astrocytic marker GFAP (R=0.69), however, sug-
gests that the rise of S100B in late gestation may be at least in part due to
activation of the glial system. The pathological role of the glial system inBSP in spina biﬁda 10
SB has not been investigated in detail and we would like to speculate that
preservation of tissue homoeostasis may be one important function. Ad-
ditionally astrocytic hypertrophy is observed rapidly after axonal injury,27
which might be of relevance in SB, as seen below.
The results for NfH were similar to those for GFAP, with a signiﬁcant
increase in amniotic ﬂuid NfH being observed in SB fetuses at E16.5 and
E18.5. Moreover, the concentration of NfH correlated directly with the size
of the MMC, at both E16.5 and E18.5. Hence, NfH levels were signiﬁcantly
higher in mice with a large SB lesion than in those with a small MMC.
In previous human studies, concentrations of NfH in the cerebrospinal
ﬂuid and plasma have been related to disability on clinical scales.28–31
Moreover, in a mouse model of chronic experimental autoimmune en-
cephalomyelitis, the NfH content of tissue homogenate was related to
spinal cord atrophy.10 In a study focused on neuroprotection, NfH was
used as a secondary outcome measure and correlated with motor func-
tion.32 The present results suggest that the NfH concentration in amniotic
ﬂuid might provide a tool to estimate the extent of axonal loss in vivo in SB
pregnancies.
In utero surgery is now offered as a clinical treatment for meningomye-
locele,6 although the optimal timing of the intervention remains a critical
issue.5 This and other aspects of human in utero surgery for MMC are cur-
rently being investigated by a multicentered prospective study in the USA:
Management of Myelomeningocele Study (MOMS, www.spinabiﬁdamoms.com).BSP in spina biﬁda 11
On the basis of the present results, it would be important to establish cut–
off levels related to fetal–age for GFAP and NfH in normal human amniotic
ﬂuid. In pregnancies with fetal SB a slight increase of GFAP and NfH would
be in keeping with the expected slowly progressive pathology, and would
indicate that surgery might be a viable option. On the other hand, once an
accelerating increase in BSP concentration was observed, suggestive of
dramatic tissue loss, it might be considered that in utero coverage would
offer only limited beneﬁts, and should be weighed carefully against the
risks for mother and child.
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Table 1: Classifying MMC size in curly tail/loop–tail fetuses.
Lengths shown are the ranges typically seen in the study. Ra-
tio = Total body length / MMC length.
Gestational age
Size E16.5 E18.5 Ratio
Total body length (mm) 15–18 26–28 —
Large MMC length (mm) 3-5 4-6 < 10





















































































































































































































































































































































































































































































































































8BSP in spina biﬁda 19
(A)
(B)
Figure 1: The curly tail/loop tail mouse model. Large (A) and small (B)



































Figure 2: Amniotic ﬂuid levels of GFAP in control (closed circles) and SB
mice (open circle). Note that for clarity of the ﬁgure, all zero values are
plotted in the hatched area and concentrations are presented in [ng/mL],































Figure 3: Mean ( 1 standard deviation) amniotic ﬂuid levels of NfH in
control (CTRL), SB mice with small MMC and SB mice with large MMC at
E16.5 and E18.5. There was no statistically signiﬁcant difference between
the NfH concentration in small MMC and controls.